Firms hope to produce an assay that can predict the risk of cardiovasular disease and heart attacks.

Transgenomic renewed a collaboration with Fiuotecnica  to produce and market a genetic panel assay to predict the risk of cardiovascular disease and heart attacks using Transgenomic’s WAVE® System.

Transgenomic will supply its WAVE System technology and related reagents to Fiuotecnica. Upon completion of the assay development, Fiuotecnica will retain rights to market the cardiovascular panel in Italy, while Transgenomic will obtain rights to market the assay in the rest of the world.

“Fiuotecnica has evaluated other platforms, but we believe that Transgenomic’s unique technology platforms, including the WAVE System for DHPLC analysis and Surveyor Nuclease, provide the highest sensitivity for mutation detection,” states Antonio Mele, CEO of Fiuotecnica.

Previous articleKineMed and Bayer Healthcare to Discover New Therapeutic Applications for Candidates
Next article4SC Receives Patent on Rheumatoid Arthritis Candidate